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Vitiligo is a disorder that causes the presence of pale patchy 
areas of depigmented skin on the face, hands and wrists; 
these patches are initially small, but often grow and change 
in shape (1). The disorder is classified in segmental vitiligo 
(SV) and non-SV (NSV): (I) in NSV there is usually a 
symmetry in the location of depigmentation; (II) SV differs 
in appearance, and it is not associated with autoimmune 
diseases (2). There are many therapies for vitiligo, the most 
used are local steroids and ultraviolet light. Vitiligo is an 
autoimmune skin disease arising from an aberrant immune 
responses against melanocytes. The existence of various 
associations between vitiligo and other autoimmune diseases 
has been proved. Generalized vitiligo is a component 
of the APECED (APS1) and Schmidt (APS2) multiple 
autoimmune disease syndromes, pernicious anemia and 
Addison’s disease (3). Thyroid disease, autoimmune thyroid 
disease (4) and presence of thyroid specific autoantibodies 
have a mean prevalence of, respectively, 15%, 14% and 
21% in patients with vitiligo (5). 
Genetic and environmental factors are important in the 
pathogenesis of vitiligo. Genetic studies concern mainly 
patients with NSV. Genomewide linkage studies and 
genome-wide association studies (GWAS) are the “gold 
standard” for detecting susceptibility genes (6). Up to now, 
about 36 NSV susceptibility loci have been identified: 
90% encode immunoregulatory proteins; 10% encode 
melanocyte proteins. In the major histocompatibility 
complex region, major associations were identified in the 
class I gene region (between HLA-A and HLA-HGC9) 
and class II gene region (between HLA-DRB1 and HLA-
DQA1). Other associations were identified with PTPN22, 
LPP, IL2RA, GZMB, UBASH3A and C1QTNF6 genes, 
which are implicated in autoimmune diseases (6). Among 
melanocyte proteins TYR encodes tyrosinase, which is an 
enzyme that catalyzes melanin biosynthesis, and it is a major 
autoantigen that is implicated in generalized vitiligo (7). 
Another gene associated with vitiligo is the NALP1 gene, 
which regulates inflammation and cell death of myeloid 
and lymphoid cells. NALP1 produces inflammatory 
products such as caspase1 and caspase7, which activate the 
cytokine interleukin-1beta which is expressed at high levels 
in patients with vitiligo (8). TSLP gene encodes thymic 
stromal lymphopoietin that induces naive CD4+ T cells to 
produce cytokines that induce a T helper (Th)2 response 
[IL-4, IL-5, IL-13, tumor necrosis factor (TNF)-α] and 
inhibit production of Th1cytokines [IL-10, interferon 
(IFN)-γ] (9). The deficiency of TSLP gene expression 
produces the dominance of the Th1 immune response, 
which is involved in vitiligo development.
IFN-γ is the most important cytokine, that is associated 
with the Th1 immune response (10). This cytokine acts 
through chemokines that are small glycoproteins active for a 
wide variety of cell types. The IFN-γ-inducible protein (IP)-
10, also called chemokine (C-X-C motif) ligand (CXCL)10, 
was identified as a chemokine that is induced by IFN-γ 
in various cell types, such as neutrophils, lymphocytes, 
endothelial cells, fibroblasts, thyrocytes and other epithelial 
cells (11,12). CXCL10 binds to its specific receptor, 
chemokine (C-X-C motif) receptor (CXCR)3, and regulates 
immune responses by recruitment and activation of T cells, 
monocytes, and natural killer cells. CXCR3 is expressed not 
only by immune cells but also by endothelial cells, mesangial 
cells, thyrocytes and other epithelial cells. Recently, it has 
been shown that the tissue expressions of CXCR3 and 
CXCL10 are increased in various autoimmune diseases, 
and that they play fundamental parts in leukocyte homing 
into the inflamed tissues and contribute to the process of 
tissue damage (12). Determination of high level of CXCL10 
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in peripheral liquids is a marker of host immune response, 
especially of a Th1 orientated immune response. In inflamed 
tissues recruited Th1 lymphocytes are responsible for 
enhanced IFN-γ and TNF-α production, which in turn 
stimulate CXCL10 secretion from a variety of the above 
mentioned cells, therefore creating an amplification feedback 
loop (13).
It has been recently reported that the serum and/or 
the tissue CXCL10 expressions are increased in organ 
specific autoimmune diseases, such as type 1 diabetes, 
Graves’ disease, or Graves’ ophthalmopathy, or systemic 
rheumatological disorders like rheumatoid arthritis, 
systemic lupus erythematosus, systemic sclerosis and HCV-
related cryoglobulinemia (13).
A modulatory role of peroxisome proliferator-activated 
receptor-γ or -α agonists on CXCR3 chemokines in 
autoimmune disorders has been shown, and further studies 
are ongoing to explore the use of new molecules that act as 
antagonists of CXCR3, or block CXCL10, in autoimmune 
diseases (13-16).
The role of CXCL10 in the immunopathogenesis of 
vitiligo has been highlited in three new studies (17-19).
It has been shown that intercellular adhesion molecule-1 
(ICAM-1) expression has been detected in melanocytes 
around active vitiligo. Moreover, it has been shown 
that RNA released from necrotic keratinocytes induced 
the upregulation of ICAM-1, through activation of 
nuclear factor κ-light-chain-enhancer of activated B cells 
(NF-κB). This process was associated with a dramatic 
increase in proinflammatory cytokine and chemokine 
transcripts (CXCL10, CXCL11, etc.) (17).
More importantly, a recent study reports that both 
human vitiligo and a mouse model of vitiligo reflect an 
IFN-γ-specific Th1 immune response in the skin that 
involves the IFN-γ-dependent chemokines CXCL9, 10, and 
11 (18). 
To identify the key cytokine pathways in vitiligo, 
the gene expression profile in lesional skin patches of 
vitiligo patients was measured, which contained a T cell 
infiltrate. Compared to healthy controls, a significant 
loss of melanocyte-specific transcripts in lesional skin 
was observed, while chemokine expression revealed a 
predominantly Th-mediated signature (IFNG-specific). Th1 
chemokines CXCL9, CXCL10, CXCL11, and CCL5 were 
highly induced in vitiligo, in comparison with adhesion 
molecules ICAM1and VCAM1. In serum of vitiligo patients 
CXCL10 level was high, while CXCL9 and CXCL11 
were not significantly different from healthy controls. 
Melanocyte-specific CD8+ T cells expressed CXCR3 (the 
common receptor for CXCL9, CXCL10 and CXCL11, 
unlike healthy controls (18). 
A mouse model of vitiligo was also used (19). Krt14-Kitl* 
mice have a number of epidermal melanocytes, similar to 
human skin; following transfer of premelanosome protein-
specific CD8+ T cells (PMELs) and in vivo activation 
recombinant vaccinia virus expressing their cognate 
antigen (PMEL), Krt14-Kitl* mice develop epidermal 
depigmentation on their foot pads, ears, and tails. Profiling 
of lesional skin from this mice with vitiligo showed a gene 
chemokines expression similar to human vitiligo, with a 
Th1-specific response in the skin, and expression of the 
IFN-γ-dependent chemokines CXCL9, CXCL10, and 
CCL5. Autoreactive T cells express CXCR3, similarly 
to what observed in humans with disease (18). It was also 
evaluated that if CXCR3 is required for the development 
of depigmentation, by transferring either wild-type or Cxcr3−/−
PMEL T cells to induce vitiligo, and it was observed that 
Cxcr3−/− T cells were unable to induce depigmentation (18). 
In this mouse model of vitiligo, Cxcl10−/− hosts developed 
minimal depigmentation suggesting that vitiligo depends on 
this chemokine. CXCL10 plays a role in directed migration 
within the skin of T cells, and it was required for T cell 
function beyond simple recruitment (18). When mice 
were treated with either CXCL9 or CXCL10 neutralizing 
antibodies, neutralization of CXCL10 significantly reduced 
depigmentation in this model, while neutralization of 
CXCL9 did not. Surprisingly, CXCL10 neutralization in 
mice with established, widespread depigmentation induces 
reversal of disease, evidenced by repigmentation. These data 
identify a critical role for CXCL10 in both the progression 
and maintenance of vitiligo and thereby support inhibiting 
CXCL10 as a targeted treatment strategy (18).
On the base of the results obtained from this important 
study (18), it was evaluated the effect of inhibition of IFN-γ 
in vitiligo. STAT1 activation is required for IFN-γ signaling 
and recent studies revealed that simvastatin, an FDA-
approved cholesterol-lowering medication, inhibited STAT1 
activation in vitro (20). Therefore, it was hypothesized that 
simvastatin may be an effective treatment for vitiligo. In fact, 
simvastatin both prevented and reversed depigmentation 
in the mouse model of vitiligo, and reduced the number 
of infiltrating autoreactive CD8+ T cells in the skin. 
Treatment of melanocyte-specific, CD8+ T cells in vitro 
decreased proliferation and IFN-γ production, suggesting 
additional effects of simvastatin directly on T cells. Based on 
these data, it has been suggested that simvastatin may be a 
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safe, targeted treatment option for patients with vitiligo (20).
The above mentioned results (18,20) show the importance 
of the Th1 immune response in the development of 
vitiligo, and of CXCR3 receptor and its chemokine 
CXCL10, suggesting these could be novel targets of future 
therapeutical approaches. Further studies are needed to 
explore the use of new molecules that act as antagonists of 
CXCR3, or block CXCL10, in vitiligo in a clinical setting.
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